CN110709081B - 用于治疗细菌感染的化合物及方法 - Google Patents

用于治疗细菌感染的化合物及方法 Download PDF

Info

Publication number
CN110709081B
CN110709081B CN201880030289.8A CN201880030289A CN110709081B CN 110709081 B CN110709081 B CN 110709081B CN 201880030289 A CN201880030289 A CN 201880030289A CN 110709081 B CN110709081 B CN 110709081B
Authority
CN
China
Prior art keywords
int
mmol
oxo
methanopyrazolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880030289.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110709081A (zh
Inventor
贾内尔·科米塔-普莱瓦尔
托马斯·佛朗索瓦·杜兰德-雷维尔
萨泰尼格·古勒
扬·罗梅罗
马克·西尔韦斯特
鲁本·托马西
卡米洛·维莱斯-韦加
吴晓云
张靖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ntassis Treatment
Original Assignee
Ntassis Treatment
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ntassis Treatment filed Critical Ntassis Treatment
Publication of CN110709081A publication Critical patent/CN110709081A/zh
Application granted granted Critical
Publication of CN110709081B publication Critical patent/CN110709081B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880030289.8A 2017-05-08 2018-05-08 用于治疗细菌感染的化合物及方法 Active CN110709081B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
US62/502,867 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (2)

Publication Number Publication Date
CN110709081A CN110709081A (zh) 2020-01-17
CN110709081B true CN110709081B (zh) 2023-09-22

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030289.8A Active CN110709081B (zh) 2017-05-08 2018-05-08 用于治疗细菌感染的化合物及方法

Country Status (27)

Country Link
US (1) US11046694B2 (enExample)
EP (1) EP3630111B1 (enExample)
JP (1) JP7058322B2 (enExample)
KR (1) KR102611447B1 (enExample)
CN (1) CN110709081B (enExample)
AU (1) AU2018266640B2 (enExample)
CA (1) CA3059773A1 (enExample)
CY (1) CY1125340T1 (enExample)
DK (1) DK3630111T3 (enExample)
EA (1) EA038393B1 (enExample)
ES (1) ES2907858T3 (enExample)
HR (1) HRP20220231T1 (enExample)
HU (1) HUE057592T2 (enExample)
IL (1) IL270380B (enExample)
LT (1) LT3630111T (enExample)
MA (1) MA48743A (enExample)
MX (1) MX385203B (enExample)
MY (1) MY201377A (enExample)
PE (1) PE20200333A1 (enExample)
PH (1) PH12019502509A1 (enExample)
PL (1) PL3630111T3 (enExample)
PT (1) PT3630111T (enExample)
SG (1) SG11201909443YA (enExample)
SI (1) SI3630111T1 (enExample)
SM (1) SMT202200110T1 (enExample)
TW (1) TWI791018B (enExample)
WO (1) WO2018208769A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN115605480B (zh) 2021-05-07 2024-04-05 宁夏农林科学院 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2025064681A1 (en) * 2023-09-19 2025-03-27 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005325210A1 (en) * 2004-07-30 2006-07-27 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
CN103649088A (zh) * 2011-08-30 2014-03-19 沃克哈特有限公司 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
CN104364254A (zh) * 2012-04-02 2015-02-18 阿斯利康(瑞典)有限公司 作为β-内酰胺酶抑制剂的杂二环化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69416869T2 (de) 1993-12-29 1999-07-01 Pfizer Inc., New York, N.Y. Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
PL2231667T3 (pl) 2008-01-18 2014-01-31 Merck Sharp & Dohme Inhibitory beta-laktamazy
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CN103687598B (zh) 2011-07-26 2016-03-16 沃克哈特有限公司 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
EP2748165B1 (en) 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
ES2640520T3 (es) 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β－內醯胺酶抑制劑
US8916709B2 (en) * 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
CN104334559B (zh) 2012-05-30 2017-03-22 明治制果药业株式会社 β‑内酰胺酶抑制剂及其制备方法
AU2013308127B2 (en) 2012-08-25 2015-08-13 Wockhardt Limited 1,6- Diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
CN104768547A (zh) 2012-09-03 2015-07-08 沃克哈特有限公司 抗菌组合物
CA2897446A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
ME03357B (me) 2014-11-17 2019-10-20 Entasis Therapeutics Ltd Kombinovana terapija za lečenje rezistentnih bakterijsкih infekcija
KR102537340B1 (ko) 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005325210A1 (en) * 2004-07-30 2006-07-27 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
CN103649088A (zh) * 2011-08-30 2014-03-19 沃克哈特有限公司 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途
CN104364254A (zh) * 2012-04-02 2015-02-18 阿斯利康(瑞典)有限公司 作为β-内酰胺酶抑制剂的杂二环化合物
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Also Published As

Publication number Publication date
KR102611447B1 (ko) 2023-12-06
ES2907858T3 (es) 2022-04-26
IL270380B (en) 2022-06-01
EP3630111B1 (en) 2021-11-24
EP3630111A1 (en) 2020-04-08
WO2018208769A1 (en) 2018-11-15
CA3059773A1 (en) 2018-11-15
MX2019013291A (es) 2020-01-15
PH12019502509A1 (en) 2020-07-13
BR112019023130A2 (pt) 2020-05-26
CY1125340T1 (el) 2024-02-16
MY201377A (en) 2024-02-21
US11046694B2 (en) 2021-06-29
HUE057592T2 (hu) 2022-05-28
JP2020519687A (ja) 2020-07-02
KR20200005586A (ko) 2020-01-15
MA48743A (fr) 2020-04-08
MX385203B (es) 2025-03-14
US20200165251A1 (en) 2020-05-28
PT3630111T (pt) 2022-03-01
EA038393B1 (ru) 2021-08-20
DK3630111T3 (en) 2022-03-14
SG11201909443YA (en) 2019-11-28
SI3630111T1 (sl) 2022-05-31
AU2018266640B2 (en) 2022-03-03
SMT202200110T1 (it) 2022-05-12
TW201843152A (zh) 2018-12-16
AU2018266640A1 (en) 2019-11-07
TWI791018B (zh) 2023-02-01
PE20200333A1 (es) 2020-02-14
JP7058322B2 (ja) 2022-04-21
PL3630111T3 (pl) 2022-05-23
LT3630111T (lt) 2022-03-10
HRP20220231T1 (hr) 2022-04-29
EA201992370A1 (ru) 2020-03-10
CN110709081A (zh) 2020-01-17

Similar Documents

Publication Publication Date Title
CN110709081B (zh) 用于治疗细菌感染的化合物及方法
TW201446758A (zh) 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
US11078198B2 (en) Spirocyclic compounds as farnesoid X receptor modulators
US20140275056A1 (en) P2x7 modulators
CN112638381A (zh) 毒蕈碱性乙酰胆碱m1受体拮抗剂
AU2016257338B2 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
TW200914457A (en) Pyrimidodiazepinone derivative
US20210053926A1 (en) Substituted benzazinones as antibacterial compounds
WO2018045971A1 (zh) 吡啶并五元芳香环类化合物、其制备方法及用途
CN117769548A (zh) 芳香乙炔类衍生物及其制备方法和用途
WO2018129008A1 (en) Compounds and methods for treating bacterial infections
HK40026676B (en) Compounds and methods for treating bacterial infections
CN107108646A (zh) 阿根诺卡菌素类化合物及其作为抗菌剂的用途
BR112019023130B1 (pt) Compostos antibacterianos, composição farmacêutica que os compreende, e usos dos mesmos
TW202045492A (zh) P300/cbp hat抑制劑及其使用方法
US20250066356A1 (en) Lrrk2 inhibitors
JP2025541737A (ja) Ｍａｓｐ－２阻害物質としての縮合ピリミジン

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant